Spiral Genetics

Belkins
Compromised of a diverse team of highly talented technical and scientific individuals, Spiral Genetics is a leader in software for population genomics, developing the world's most advanced bioinformatics technology.

Related News

NOVAVAX, ADVANCING COVID-19 SHOT, RECRUITS ASTRAZENECA EXEC AS ITS CHIEF MEDICAL OFFICER

Fiercepharma | June 17, 2020

news image

On the heels of some big fundraising moves and in the hunt for a COVID-19 vaccine, Novavax is adding some Big Pharma experience to its executive team. Joining the company's leadership team as chief medical officer is Filip Dubovsky, an AstraZeneca veteran. Dubovsky joins Novavax directly from the British drugmaker, where he served as head of clinical engagement and policy, plus as chief medical officer for clinical affairs. Before that role, he oversaw a portfolio of more than two doze...

Read More

BUSINESS INSIGHTS

HARROW HEALTH ACQUIRES OPHTHALMIC SURGICAL DRUG CANDIDATE FROM WAKAMOTO PHARMACEUTICAL CO., LTD.

Harrow Health, Inc. | August 18, 2021

news image

Harrow Health, Inc. an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Wakamoto Pharmaceutical Co., Ltd. to acquire the U.S. and Canadian commercial rights for drug candidate MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection. MAQ-100 is marketed and sold by Wakamoto in Japan as MaQaid®. Following Japan’s Ministry of Health Labor and Welfare (or MHLW) approval, MaQaid was launched in Japan in 2010, ...

Read More

PHARMACY MARKET

YANGTZE RIVER PHARMACEUTICAL GROUP SELECTS TRACELINK PLATFORM FOR GLOBAL COMPLIANCE

Yangtze River Pharmaceutical, TraceLink | May 06, 2021

news image

TraceLink Inc., the leading digital network platform company, today announced that Yangtze River Pharmaceutical Group has selected TraceLink's global compliance solution to aid its plans for global growth. As the company gears up for international market expansion this year, Yangtze River Pharmaceutical Group (YRPG) will use TraceLink's multienterprise compliance applications and industry-leading digital supply network to comply with track and trace requirements in multiple markets, incl...

Read More

CORONAVIRUS TRACKER: GILEAD'S REMDESIVIR; WHITE HOUSE'S VACCINE PROJECT; PFIZER, BIONTECH'S VACCINE PROGRESS; ASTRAZENECA'S PIPELINE

Fiercepharma | April 29, 2020

news image

As headlines multiplied and analysts began sussing out Gilead Sciences' first controlled trial readout on remdesivir, NIAID director Anthony Fauci hailed the drug as real progress against the virus. Meanwhile, word emerged that the Trump administration is working up a Manhattan Project style vaccine initiative, bringing biotech, pharma and federal agencies together to speed up the work—and let the U.S. government take on the financial risks. Plus, Pfizer and BioNTech said they've d...

Read More

Fiercepharma | June 17, 2020

news image

NOVAVAX, ADVANCING COVID-19 SHOT, RECRUITS ASTRAZENECA EXEC AS ITS CHIEF MEDICAL OFFICER

On the heels of some big fundraising moves and in the hunt for a COVID-19 vaccine, Novavax is adding some Big Pharma experience to its executive team. Joining the company's leadership team as chief medical officer is Filip Dubovsky, an AstraZeneca veteran. Dubovsky joins Novavax directly from the British drugmaker, where he served as head of clinical engagement and policy, plus as chief medical officer for clinical affairs. Before that role, he oversaw a portfolio of more than two doze...

Read More

BUSINESS INSIGHTS

Harrow Health, Inc. | August 18, 2021

news image

HARROW HEALTH ACQUIRES OPHTHALMIC SURGICAL DRUG CANDIDATE FROM WAKAMOTO PHARMACEUTICAL CO., LTD.

Harrow Health, Inc. an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Wakamoto Pharmaceutical Co., Ltd. to acquire the U.S. and Canadian commercial rights for drug candidate MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection. MAQ-100 is marketed and sold by Wakamoto in Japan as MaQaid®. Following Japan’s Ministry of Health Labor and Welfare (or MHLW) approval, MaQaid was launched in Japan in 2010, ...

Read More

PHARMACY MARKET

Yangtze River Pharmaceutical, TraceLink | May 06, 2021

news image

YANGTZE RIVER PHARMACEUTICAL GROUP SELECTS TRACELINK PLATFORM FOR GLOBAL COMPLIANCE

TraceLink Inc., the leading digital network platform company, today announced that Yangtze River Pharmaceutical Group has selected TraceLink's global compliance solution to aid its plans for global growth. As the company gears up for international market expansion this year, Yangtze River Pharmaceutical Group (YRPG) will use TraceLink's multienterprise compliance applications and industry-leading digital supply network to comply with track and trace requirements in multiple markets, incl...

Read More

Fiercepharma | April 29, 2020

news image

CORONAVIRUS TRACKER: GILEAD'S REMDESIVIR; WHITE HOUSE'S VACCINE PROJECT; PFIZER, BIONTECH'S VACCINE PROGRESS; ASTRAZENECA'S PIPELINE

As headlines multiplied and analysts began sussing out Gilead Sciences' first controlled trial readout on remdesivir, NIAID director Anthony Fauci hailed the drug as real progress against the virus. Meanwhile, word emerged that the Trump administration is working up a Manhattan Project style vaccine initiative, bringing biotech, pharma and federal agencies together to speed up the work—and let the U.S. government take on the financial risks. Plus, Pfizer and BioNTech said they've d...

Read More